NCT00975884View on ClinicalTrials.gov

Study to Evaluate Immunogenicity & Safety of an Investigational Influenza Vaccine in Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

312

Participants

Timeline

Start Date

September 14, 2009

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Influenza
Interventions
BIOLOGICAL

GSK investigational vaccine GSK2340272A

Two intramuscular injections

Trial Locations (5)

59037

GSK Investigational Site, Lille

63003

GSK Investigational Site, Clermont-Ferrand

75679

GSK Investigational Site, Paris

75877

GSK Investigational Site, Paris

86000

GSK Investigational Site, Poitiers

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY